• G J Jacquin and B A van Adel.
• Division of Neurology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
• J. Thromb. Haemost. 2015 Jun 1; 13 Suppl 1: S290-6.

AbstractThrombolytic therapy with intravenous recombinant tissue plasminogen activator is well established as a beneficial treatment for patients presenting with acute ischemic stroke (AIS). The odds of a favorable clinical outcome (living independently) increase as the time between stroke onset and treatment with IV thrombolysis decreases. However, many patients present with a large clot burden that seldom responds to systemic fibrinolysis. Alternative options include new and emerging endovascular therapies that have recently proven effectiveness at restoring cerebral blood flow to the ischemic brain parenchyma. This review article will briefly outline some of the key evidence for intravenous thrombolysis as well as endovascular therapy for AIS. © 2015 International Society on Thrombosis and Haemostasis.

30 keywords...

hide…